Creative Medical Technology Holdings, Inc. (CELZ) 주식 분석

회사 개요

Creative Medical Technology Holdings, Inc. (CELZ) operates as a commercial-stage biotechnology enterprise dedicated to developing novel biological therapeutics across specialized medical fields including immunotherapy, endocrinology, urology, neurology, and orthopedics within the United States market. The firm's product portfolio notably includes CaverStem, which is utilized for the treatment of erectile dysfunction, alongside FemC, positioning it within the high-value biopharmaceutical sector. Currently, the company maintains a market capitalization of $7.54M, reports annual revenue of $6,000, and employs a workforce of 4 individuals. These valuation and operational figures indicate that CELZ is an extremely small-cap entity with minimal revenue generation relative to its market valuation, suggesting a business model driven primarily by asset development and future product potential rather than established commercial cash flows at this stage. The disparity between its $7.54M market cap and its negligible revenue base highlights a typical characteristic of early-stage biotech firms where investor value is placed on intellectual property and pipeline assets rather than current profitability.

재무 건전성

The company's financial statements reveal a significant divergence between top-line performance and bottom-line results, with TTM revenue of $6,000 contrasted sharply against a net income loss of $5,995,008 and an EBITDA of $-6,019,487. This substantial gap between minimal revenue and multi-million dollar net losses indicates a cost structure dominated by heavy research and development expenses, clinical trial costs, or operational overhead typical of the commercial-stage biotechnology lifecycle. The firm reports a free cash flow of $-3,751,198, which signifies a net cash outflow that constrains immediate financial flexibility and necessitates reliance on external capital markets or existing cash reserves to fund ongoing operations. Despite the negative operating margin of -64859.4% and a profit margin of 0.0%, the gross margin stands at 63.4%, demonstrating that the core cost of goods sold remains manageable relative to revenue, even though operating expenses are driving overall profitability into severe negative territory. On the liquidity front, CELZ holds $7.21M in cash against a relatively minor debt obligation of $14,194, resulting in a debt-to-equity ratio of 0.19. This balance sheet composition reflects a highly conservative leverage position where cash assets vastly exceed debt liabilities, providing a substantial buffer against financial distress. Furthermore, a current ratio of 25.97 indicates exceptional short-term liquidity, suggesting the company possesses more than 25 times the current assets necessary to cover its current liabilities without issue. However, return metrics paint a picture of significant capital inefficiency, with a return on equity of -86.5% and a return on assets of -53.0%, revealing that management is currently destroying shareholder value through substantial losses rather than generating positive returns on the capital deployed.

밸류에이션 평가

Valuation multiples for Creative Medical Technology Holdings reflect its lack of profitability, with a trailing P/E ratio of N/A due to negative earnings and a forward P/E of -1.51, which implies that the market is pricing in future earnings recovery but acknowledges the current unprofitability. The price-to-book ratio is stated at 1.00, indicating that the market values the company exactly at its book value, which suggests a neutral assessment of the company's tangible assets without a significant premium or discount. Alternative valuation metrics further highlight the speculative nature of the stock, as the price-to-sales ratio is extremely high at 1256.87 and the EV/EBITDA stands at -0.06, both figures signaling that traditional valuation methods are not applicable due to the absence of meaningful earnings or sales volume relative to the stock price. The stock price has fluctuated significantly over the past year, trading between a 52-week low of $1.50 and a 52-week high of $6.25, with the current trading price situated somewhere within this volatile range dependent on daily market movements. The beta value of 1.99 indicates that the stock price is nearly twice as volatile as the broader market, meaning that CELZ experiences amplified price swings during periods of market instability compared to large-cap blue-chip stocks.

Growth & Income

The company's growth profile is characterized by stagnation in top-line growth and an absence of reported earnings growth, with revenue growth year-over-year at 0.0% and earnings growth year-over-year listed as N/A. The lack of revenue growth combined with deep losses suggests that the company is not yet in a phase of commercial expansion where earnings growth outpaces revenue, but rather remains in a development or maintenance phase where revenue generation is limited. As a non-dividend payer, CELZ does not distribute any income to shareholders, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, which means the company retains all resources to potentially fund R&D or operational needs rather than rewarding investors with cash distributions. Consequently, the overall growth and income profile of Creative Medical Technology Holdings is defined by zero current income generation and zero revenue expansion, relying entirely on future product launches or partnerships to alter its financial trajectory.